Hutchison China MediTech, a CK Hutchison-backed pharmaceutical with a pipeline of oncology candidates, raised $101 million by offering 7.5 million ADSs at $13.50. In its most recent filing, the company expected to raise $100 million by offering 6.1 million ADSs at $16.33, its last traded price on the AIM market in London. Hutchison China MediTech plans to list on the Nasdaq under the symbol HCM. BofA Merrill Lynch and Deutsche Bank acted as lead managers on the deal.
